Australasian Leukaemia and Lymphoma Group
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hamad, Nada
NCT04202835: ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Recruiting
2
80
Canada, RoW
Cyclophosphamide, Anti-Thymocyte globulin (rabbit), Thymoglobulin
McMaster University, Cell Therapy Transplant Canada, Sanofi, Ozmosis Research Inc.
Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
10/24
12/24
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
1
55
US, RoW
CB-5339, CB-5339 Tosylate
Cleave Therapeutics, Inc.
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
07/23
07/23
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruiting
1
150
US, RoW
NKX019
Nkarta, Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
03/25
12/38
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hamad, Nada
NCT04202835: ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Recruiting
2
80
Canada, RoW
Cyclophosphamide, Anti-Thymocyte globulin (rabbit), Thymoglobulin
McMaster University, Cell Therapy Transplant Canada, Sanofi, Ozmosis Research Inc.
Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
10/24
12/24
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
1
55
US, RoW
CB-5339, CB-5339 Tosylate
Cleave Therapeutics, Inc.
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
07/23
07/23
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruiting
1
150
US, RoW
NKX019
Nkarta, Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
03/25
12/38

Download Options